The article discusses the potential of 212Pb as a promising α-emitter for radiotherapeutic applications, highlighting its advantages over other radionuclides like 177Lu and 225Ac. 212Pb has a shorter half-life, which maximizes energy deposition in tumor cells and eliminates the need for long-term hospital stays. The article reviews the development of 212Pb, noting that over 15 companies are actively working on its production, with significant progress made in chelating agents to trap 212Bi, the β-emitter in the decay sequence. 212Pb is also being explored as an alternative to cocktail therapies, offering simultaneous efficacy in larger tumors and micrometastases. Imaging with 212Pb is feasible but may be limited to development purposes, while 203Pb is proposed as a surrogate for imaging. The article details various production routes for 212Pb, including the use of generators based on the decay of 228Th and 228Ra, with several companies investing in industrial-scale production. Access to precursors 228Th and 228Ra is not a significant issue, and there is optimism that large-scale production will be available by 2028, potentially replacing 225Ac by 2035-2045.The article discusses the potential of 212Pb as a promising α-emitter for radiotherapeutic applications, highlighting its advantages over other radionuclides like 177Lu and 225Ac. 212Pb has a shorter half-life, which maximizes energy deposition in tumor cells and eliminates the need for long-term hospital stays. The article reviews the development of 212Pb, noting that over 15 companies are actively working on its production, with significant progress made in chelating agents to trap 212Bi, the β-emitter in the decay sequence. 212Pb is also being explored as an alternative to cocktail therapies, offering simultaneous efficacy in larger tumors and micrometastases. Imaging with 212Pb is feasible but may be limited to development purposes, while 203Pb is proposed as a surrogate for imaging. The article details various production routes for 212Pb, including the use of generators based on the decay of 228Th and 228Ra, with several companies investing in industrial-scale production. Access to precursors 228Th and 228Ra is not a significant issue, and there is optimism that large-scale production will be available by 2028, potentially replacing 225Ac by 2035-2045.